Oprozomib (ONX 0912), an inhibitor for CT-L activity of 20S proteasome β5(IC50=36 nM)/LMP7(IC50=82 nM), is orally bioavailable. Oprozomib also has potential antineoplastic activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 109 | |
4 mg | In stock | $ 185 | |
8 mg | In stock | $ 310 | |
20 mg | In stock | $ 576 | |
40 mg | In stock | $ 864 |
Description | Oprozomib (ONX 0912), an inhibitor for CT-L activity of 20S proteasome β5(IC50=36 nM)/LMP7(IC50=82 nM), is orally bioavailable. Oprozomib also has potential antineoplastic activity. |
Targets&IC50 | 20S proteasome β5:36 nM, 20S proteasome LMP7:82 nM |
Synonyms | ONX 0912, PR-047 |
CAS No. | 935888-69-0 |
Chemical Formula | C25H32N4O7S |
Molecular Weight | 532.61 |
Solubility | H2O: <1 mg/mL DMSO: 93 mg/mL (174.6mM); Ethanol: <1 mg/mL |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom